Citation Impact
Citing Papers
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
2003 Standout
Transfer of drugs and other chemicals into human milk
1989
Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
2017 Standout
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
1989 Standout
Cancer immunoediting: from immunosurveillance to tumor escape
2002 Standout
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres
2002 StandoutNobel
Pharmacology and Management of the Vitamin K Antagonists
2008 Standout
A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints
2005 Standout
Randomized Study Comparing Carboplatin/Cyclophosphamide and Cisplatin/Cyclophosphamide as First-Line Treatment in Patients with Stage III/IV Epithelial Ovarian Cancer and Small Volume Disease
1997
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
1991 Standout
A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives
1989
Receptor Specificity of the Fibroblast Growth Factor Family
1996 Standout
First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
2002
A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel
2001 Standout
Meta-analysis of surgery in advanced ovarian carcinoma: Ismaximum cytoreductive surgery an independent determinant of prognosis?
1992
Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice
2002 StandoutNobel
Advanced epithelial ovarian cancer: salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy.
1988
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
1996 Standout
Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy.
1987
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome
2005
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
1996 Standout
Molecular mechanisms of cisplatin resistance
2011 Standout
Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy
2008 Standout
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
Developmental chemotherapy in advanced ovarian cancer: Incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182)
2002
The central nervous system in the Apert syndrome
1990
Cellular processing of platinum anticancer drugs
2005 Standout
Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome
1995 Standout
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity
2002
Advances and Challenges of Liposome Assisted Drug Delivery
2015 Standout
Anesthesia, Cardiopulmonary Bypass, and the Pregnant Patient
1991
Chemotherapy with high dose ifosfamide/mesna plus cisplatin for the treatment of ovarian cancer: A study of the Grupo de Estudio y Tratamiento Latino‐Americano del cancer
1991
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
1999 Standout
Advanced epithelial ovarian carcinoma: Long-term survival experience at the community hospital
1992
Publication bias in clinical research
1991 Standout
Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
1989
Epirubicin
1993
Funnel plots for detecting bias in meta-analysis
2001 Standout
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
2012 Standout
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
2001 Standout
Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer.
1997
Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
1989
Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer
1988
Neuroblastoma
2007 Standout
Native Valve Endocarditis Due to Corynebacterium striatum: Case Report and Review
1994
Coffee and Health: A Review of Recent Human Research
2006 Standout
The Pharmacology and Management of the Vitamin K Antagonists
2004 Standout
Adverse effects of anti-tumor drug, cisplatin, on rat kidney mitochondria: Disturbances in glutathione peroxidase activity
1989
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer
2004
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
1997
Long-Term Results in Patients with Advanced Epithelial Ovarian Carcinoma Treated with a Combination of Cisplatin, Doxorubicin, and Cyclophosphamide
1997
Cancer of the Ovary
2004 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Nicotine replacement therapy for smoking cessation
2012 Standout
Clinical pharmacology of intraperitoneal cisplatin
1985
Salvage therapy with whole-abdominal irradiation in patients with advanced carcinoma of the ovary previously treated by combination chemotherapy
1986
Corynebacterial endocarditis. A report of two cases with review
1967
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway
2017 StandoutNobel
Prophylaxis of thromboembolism in pregnancy: an alternative
1985
2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis
2016 Standout
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
2014 Standout
THE EFFECTIVENESS OF AN ORAL VITAMIN K1 IN CONTROLLING EXCESSIVE HYPOPROTHROMBINEMIA DURING ANTICOAGULANT THERAPY
1956
Infections Caused by Nondiphtheria Corynebacteria
1982
Dose intensity analysis of chemotherapy regimens in ovarian carcinoma.
1987
Full publication of results initially presented in abstracts
2007 Standout
Infection Due to Corynebacterium Species in Marrow Transplant Patients
1979 StandoutNobel
Confronting publication bias: A cohort design for meta‐analysis
1987
Original article: Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma
1990
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
2003 Standout
Histologic correlates of virulence in ovarian adenocarcinoma
1982
Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial.
1985
Clinical microbiology of coryneform bacteria
1997 Standout
Second-Line Chemotherapy in Relapsing or Refractory Non–Small-Cell Lung Cancer: A Review
2000
Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.
1992
Infant Neurobehavior Following Prenatal Exposure to Methadone or Buprenorphine: Results From the Neonatal Intensive Care Unit Network Neurobehavioral Scale
2010
Publication bias: the case for an international registry of clinical trials.
1986
Factors Influencing Publication of Research Results
1992 Standout
Diphtheroid Bacterial Endocarditis After Insertion of a Starr Valve
1966
Chemotherapy of drug-resistant ovarian cancer: a Southwest Oncology Group Study.
1986
Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent
1985
Publication bias in clinical trials due to statistical significance or direction of trial results
2009 Standout
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
2010 Standout
RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMA
1984
A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study
1986
Staging Procedures, Clinical Management, and Survival Outcome for Ovarian Carcinoma
1993
Preclinical studies identifying carboplatin as a viable cisplatin alternative
1985
SERIOUS INFECTIONS CAUSED BY DIPHTHEROIDS*
1970
Works of Robert C. Wallach being referenced
All-trans retinoic acid and interferon-?-2a in patients with metastatic or recurrent carcinoma of the uterine cervix
1997
Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer
1983
Treatment of chemotherapy-resistant advanced ovarian cancer with a combination of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (CHAP)
1981
Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation)
1983
COMBINED ANTIBIOTIC THERAPY
1951
Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycin
1981
Pregnancy in narcotics addicts treated by medical withdrawal
1969
Apert syndrome and fetal hydrocephaly
1986
Activity and Pharmacodynamics of 21-Day Topotecan Infusion in Patients With Ovarian Cancer Previously Treated With Platinum-Based Chemotherapy
1999
Clinical use of a new anticoagulant, phenylindanedione
1953
Dextran therapy for pregnancy-associated deep thrombophlebitis
1972
Methadone maintenance, pregnancy, and progeny.
1973
Methadone assays in pregnant women and progeny
1975
Drug addiction in pregnancy and the neonate
1976
Combination chemotherapy for ovarian carcinoma with cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II) after failure of initial chemotherapy.
1978